ARC’s own Kristen Hsu presented the most current updates for the clinical trial landscape, with a focus on AL amyloidosis. Kristen also discussed the direction future research.
The webinar concluded with a Q and A session.
Original Presentation Date:
September 13, 2024
0:00 — Intro
3:32 — What is a Clinical Trial?
9:26 — Should I Participate in a Trial?
12:07 — AL Amyloidosis Treatment Approaches
19:20 — AL Amyloidosis Clinical Trials
20:10 — AQUARIUS (Daratumumab; Monoclonal Antibody)
22:51 — LINKER-AL2 (Linvoseltamab; Bispecific Antibody)
24:48 — ABBV-383 (Bispecific Antibody)
26:56 — NEXICART-2 (NXC-201; CAR-T Cell Therapy)
29:14 — AFFIRM-AL (Birtamimab; Anti-Amyloid Antibody)
32:41 — Future Drug Development
33:52 — Other Clinical Trials
37:38 — How to Find Clinical Trials
40:43 — Q&A Session
42:55 — How do you find clinical trials in the UK?
43:37 — Do AL fibril treatments work for other types of amyloidosis?
44:50 — How is “relapsed” defined?
46:47 — Can you comment on CAEL-101?
48:06 — What is the correlation between amyloidosis and minority ethnic groups?
49:12 — What is t(11;14)?
50:14 — Are there any trials targeting GI involvement?
52:13 — Are imaging studies on MyAmyloidosisPathfinder.org (MAP)? Can you comment on PYP scan in AL amyloidosis?
53:39 — Are there any studies for caregivers and family members?
55:11 — Is the stabilizer being considered for first treatments with other drugs or as maintenance in relapse cases?
56:36 — What is the role of bone marrow transplant in these studies?
58:21 — Is there anything being done for rarer types of amyloidosis?
Contact ARC:
Call +1 (617) 467-5170
Email ARC at support@arci.org
